US 12350322
Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunotherapy of diseases impacted by IL-6 dysregulation
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 12350322 (Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunotherapy of diseases impacted by IL-6 dysregulation) held by United Biomedical, Inc. expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- United Biomedical, Inc.
- Grant date
- Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K2039/55505, A61K2039/55561